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Objectives: Elevation of serum gamma-glutamyltransferase (GGT), in absence of a clinically signiﬁcant
liver damage, is often found in Myotonic Dystrophy type-1 (DM1).
In this study we investigated if a speciﬁc GGT fraction pattern is present in DM1.
Designs and methods: We compared total and fractional GGT values (b-, m-, s-, f-GGT) among patients
with DM1 or liver disease (LD) and healthy subjects (HS).
Results: The increase of GGT in DM1 and LD, vs HS, was mainly due to s-GGT (median: 32.7; 66.7; and
7.9 U/L, respectively), and b-GGT (8.5; 18.9; and 2.1 U/L). The subset of DM1 patients matched with HS with
corresponding serum GGT showed higher b-GGT (6.0 vs 4.2 U/L).
Conclusions: DM1 patients with normal total GGT values showed an alteration of the production and
release in the blood of GGT fractions. Since increased s-GGT is also found in LD, a sub-clinical liver damage
likely occurs in DM1 subjects apparently free of liver disease.
© 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Introduction
Elevation of serum gamma-glutamyltransferase (GGT), a sensitive
biomarker of liver disease, is frequently found in Myotonic Dystrophy
type-1 (DM1) [1], nevertheless, most patients fail to show a clinically
signiﬁcant liver damage. GGT values of DM1 patients are rather
associated with biomarkers of oxidative damage in vivo such as
advanced oxidation protein products (AOPP) and ferric reducing
ability of plasma (FRAP) [2]; in fact GGT is known for catalyzing free
radical formation and oxidative damage in vitro by releasing the
potent iron reducing dipeptide cysteinylglycine [3]. Clarifying the
mechanisms of GGT increase in DM1 patients might help under-
standing the pathogenesis of the disease, thus improving its
management.
Circulating GGT is a heterogeneous entity consisting of soluble
protein and several molecular complexes, provided with distinct
physico-chemical properties [4]. Recently, we set up a method to
separate these complexes on the basis of the molecular weight [5]. In
human blood, obtained from healthy subjects, this procedure allowed
the identiﬁcation of four GGT fractions: big-GGT (b-GGT),medium-GGT
(m-GGT), small-GGT (s-GGT) and free-GGT (f-GGT), with molecular
weight ranging between N2000 kDa (b-GGT) and 70 kDa (f-GGT).
The aim of the present study was to establish if a speciﬁc disease-
associated form of GGT is present in DM1 patients. Thus fractional
GGT pattern of DM1 patients has been compared with that of healthy
subjects and patients with liver disease.”
Materials and methods
Study population
Twenty-nine consecutive patients with DM1, (18 males, age 43±
12), were compared with 29 patients with miscellaneous liver disease
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(LD, 17 males, age 56±15; 15 subjects had cholestatic diseases while
14 showed steatosis not related to alcohol abuse) and 29 healthy
subjects (HS, 18males, age 45±13), of corresponding age and gender.
HS were selected in a database of 256 blood donors [6]. Liver disease
in DM1 patients was excluded on the basis of clinical examination,
ultrasound tomography, and determination of standard clinical
laboratory tests for liver disease. Two DM1 patients had been
subjected to surgery for gallstones, 5 and 8 years before being
included in the study.
A second group of controls (n=17) was established by matching
each DM1 patient with a healthy subject with corresponding gender
and serum GGT activity. In this case, since the 12 MD patients with
higher serum GGT did not ﬁnd a match out of the database of 256
blood donors, only 17 individuals were included.
The Institutional Ethics Committee approved the study and all
subjects gave informed consent.
GGT fraction analysis
Fasting plasma samples (0.02 mL) were analysed as previously
described [5] by a HPLC System Gold apparatus (Beckman 126)
equipped with a spectroﬂuorometric detector (821-FP, Jasco Europe).
Separation and quantiﬁcation of fractional GGT was obtained by gel
ﬁltration chromatography (Superose 6 HR 10/300 GL column; GE
Healthcare Europe) followed by post-column injection of the ﬂuores-
cent substrate for GGT, gamma-glutamyl-7-amido-4-methylcoumarin
(gGluAMC). Enzymatic reaction, in the presence of gGluAMC
0.030 mmol/L and glycylglycine 4.5 mmol/L, proceeded for 4.5 min in
a reaction coil (PFA, 2.6 mL) kept at the 37 °C in a water bath. The
ﬂuorescence detector operating at excitation/emission wavelengths of
380/440 nm detected the AMC signal; the intensity of the ﬂuorescence
signal was expressed in arbitrary ﬂuorescence units (f.u.). Under this
reaction conditions, area under curve is proportional to GGT activity.
Total area, between 10 and 25 mL elution volume, and fractional GGT
area was calculated by a MatLab program (Version 7 MathWorks, Inc.)
to resolve overlapping peaks; the curve ﬁtting was conducted with a
nonlinear least-squares minimization algorithm using four exponen-
tially modiﬁed Gaussian (EMG) curves. The reaction was calibrated
analysing plasma samples with known total GGT activity (standards).
The slope of the calibration curve was used to convert total and
fractional GGT area to U/L [5,6]. The sum of fractional GGT activity
represents on average the 99% of total GGT activity.
Statistical analysis was conducted by ANOVA, (Kruskal–Wallis test
followed by Dunn's multiple comparison test), except that for
matched data, where the Wilcoxon matched pair test was adopted.
Results
GGT fraction pattern in DM1 and LD patients
To establish if a speciﬁc disease-associated form of GGT is present
in DM1 patients, we compared the results with fractional GGT values
of 29 healthy subjects (HS) and in the same number of patients
affected by liver disease (LD), matched for age and gender.
In all DM1 and LD patients, independently from total GGT values,
we found the same four GGT fractions (b-, m-, s-, f-GGT) described in
the population of blood donors [6], from which we selected the 29 HS
(Fig. 1).
As expected, DM1 patients showed higher total GGT levels
(median, 25th–75th percentile: 54, 26–108 U/L) in comparison with
HS (25, 19–34 U/L), but lower than in LD group (99, 67–181 U/L;
Table 1). f-GGT was the predominant fraction in HS, but not in DM1
and LD. In fact, in the latter groups the increase of GGTwas exclusively
due to higher levels of the fractions b-GGT, m-GGT and s-GGT
(Table 1).
In comparison with LD group, DM1 patients showed lower values
of total GGT, s-GGT and f-GGT, while the fraction b-GGT and m-GGT
were not signiﬁcantly different.
Among DM1 patients, seventeen showed total GGT levels (range
14–60 U/L) within the reference values. Thus we selected a group of
healthy subjects with corresponding total GGT values to compare
fractional GGT pattern and we found that also these DM1 patients had
an altered pattern of fractional GGT. In fact, DM1 patients showed
higher b-GGT values than healthy subjects (6.0 U/L vs 4.2 U/L,
pb0.05), but lower f-GGT (11.0 U/L vs 12.4 U/L, pb0.05).
Discussion
The main ﬁnding of this study is that the increase of serum GGT in
DM1 is due to s-GGT, and to a minor extent to b-GGT, while the most
abundant GGT fraction in HS is f-GGT. Since increased s-GGT is also
found in LD, these results support the hypothesis that a sub-clinical
liver damage occurs in DM1 subjects apparently free of liver disease.
Even the subset of DM1 patients with lower total GGT values,
compared to healthy subjects matched for total GGT activity, showed
an altered pattern of GGT fractions with signiﬁcantly higher b-GGT
and lower f-GGT. Thus an early impairment of b-GGT production and
release in the blood might precede liver damage.
The pathophysiological signiﬁcance of s-GGT and b-GGT might be
different. In fact, in healthy subjects both fractions are signiﬁcantly
Fig. 1. Representative elution proﬁle of fractional GGT activity for a healthy subject
(continuous line: b-GGT 2.5 U/L, m-GGT 1.7 U/L, s-GGT 7.9 U/L, f-GGT 13.9 U/L), a
DM1 patients (dashed line: b-GGT 9.6 U/L, m-GGT 4.7 U/L, s-GGT 35.0 U/L, f-GGT
9.9 U/L) and a patient with liver disease (dotted line: b-GGT 18.9 U/L, m-GGT 6.9 U/L,
s-GGT 70.9 U/L, f-GGT 14.4 U/L). These proﬁles are representative of the median
fractional GGT distribution in the three groups.
Table 1
Total and fractional GGT values (U/L) in healthy subjects (HS), patients with
miscellaneous liver disease (LD) and patients with myotonic Dystrophy type I (DM1).
HS DM1
p vs HS
LD
p vs HS
p
DM1 vs LD
Total
GGT
24.7 (18.6–34.6) 54.3 (25.8–107.7)
b0.01
98.9 (67.2–181.2)
b0.001
b0.01
b-GGT 2.1 (1.5–5.0) 8.5 (4.9–29.4)
b0.001
18.9 (13.5–28.4)
b0.001
n.s.
m-GGT 1.0 (0.5–1.5) 3.1 (1.6–7.8)
b0.001
5.3 (3.2–7.8)
b0.001
n.s.
s-GGT 7.9 (5.7–14.8) 32.7 (10.0–53.0)
b0.001
66.7 (36.1–118.5)
b0.001
b0.01
f-GGT 12.2 (10.6–13.7) 11.1 (10.2–16.5)
n.s.
15.6 (13.3–20.0)
b0.01
b0.01
Data are median (25th–75th percentile).
Statistical analysis: Kruskal–Wallis test followed by Dunn's multiple comparison test.
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associated with AST and ALT transaminases, but b-GGT is also
independently associated with the inﬂammatory biomarker C-reactive
protein and several cardiovascular risk factors [7]. Thus, s-GGTmight be
a marker of liver damage, as suggested by its paramount increase in LD
subgroup, while b-GGT potentially correlates with tissue damage in
organs other than liver.
The idea that all serum GGT originates from the liver derives
from previous studies in subjects with cholestasis and very high
values of serum GGT. The increase of lipophylic high molecular
weight forms of GGT led to hypothesize that circulating GGT might
derive from the absorption of GGT over circulating lipoproteins [4],
such as LP-x which is speciﬁcally produced during cholestasis [4].
Nevertheless the mechanism of GGT release in blood and its tissue
origin has not been established for certain and might be different for
each fraction. We recently found that human cells of non-hepatic
origin, including normal bronchial epithelium, are able to release in
serum-free culture medium a GGT form corresponding to b-GGT [8].
This suggests that, at least in part, b-GGT might derive from the
shedding of cell membranes endowed with high GGT activity. Since
all tissues display cell membrane GGT activity, even higher than the
liver [9], the increase of b-GGT might correspond to the enhanced
GGT release from diseased tissues, other than the liver, but also to a
decreased clearance of the fraction. The idea of a differential
pathogenetic signiﬁcance for b-GGT is supported also by our ﬁnding
that it is the only fraction found within human atherosclerotic
plaques [10], where it is co-localised with oxidised LDL and CD68+
foam cells [3,11].
For this reason, if considering the prooxidant role of GGT [12] and
the connection between serum GGT and oxidative damage in vivo
in DM1 [2], identifying the source and the metabolic fate of s-GGT and
b-GGT might contribute to the understanding of the pathogenesis of
DM1, and in particular of the role played by oxidative damage in the
complex phenotype of this disease.
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